Viraleze registered for sale in Covid-ravaged India
AsiaNet 90049
MELBOURNE, Australia, June 11, 2021/PRNewswire=KYODO JBN/--
India's vast population will have access from today to the Australian developed
anti-COVID nasal spray Viraleze™ following its registration in the country.
The announcement came as the world's second most populous country battles a
devastating second wave of COVID-19 infections, with over 29 million cases and
363,000 deaths. Yesterday, India set a new global record for deaths after 6,148
people died in the previous 24 hours.
Developed by biopharmaceutical company Starpharma, Viraleze™ has shown to
inactivate a broad-spectrum of respiratory viruses, including more than 99.9%
of coronavirus SARS-CoV-2 (the virus that causes COVID-19). The product can be
applied before or after exposure and can be used in high-risk or crowded
environments up to four times a day.
Importantly for a largely rural population like India's, the spray can be
stored at room temperature and does not require cold storage or specialised
transportation.
Indian consumers can purchase the spray from www.viraleze.co and Starpharma's
discussions with commercial partners in India for distribution into both the
private (consumer) and Government markets are well advanced.
"India continues to record hundreds of thousands of COVID-19 cases every day.
Starpharma has worked extremely hard to achieve expedited registration of
Viraleze™ given the significant need," said Starpharma's CEO, Dr Jackie
Fairley.
"The active in Viraleze™, astodrimer sodium, has been shown to be highly active
against multiple strains and variants of SARS-CoV-2, including the problematic
Alpha variant( https://starpharma.com/news/589 ), which is the second most
common variant in India and has been responsible for COVID-19 cases in about
135 countries."
Viraleze™ first launched in the UK at LloydsPharmacy in March and was the
biggest selling product ever at LloydsPharmacy.com. It launched in Europe in
May.
Starpharma has received interest from more than 30 countries since launching
its webstore, including from Japan where the Olympics soon begin, and has been
in the grip of a fourth wave of COVID-19 infections.
Viraleze™ has also been ordered by several international sporting teams,
including Olympic teams. Starpharma has signed a partnership agreement for
Viraleze™ with the Harlequins rugby union team in the UK which are using the
product as part of its COVID-19 prevention protocols.
Viraleze™ complements other COVID-19 prevention strategies, including vaccines.
It has special relevance in areas of high population density, and where social
distancing is not possible and in high-risk environments such as travel, hotel
quarantine, and sporting events.
SOURCE Starpharma
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=393614
Caption: Starpharma
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。